Copyright
©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Aug 28, 2020; 26(32): 4763-4785
Published online Aug 28, 2020. doi: 10.3748/wjg.v26.i32.4763
Published online Aug 28, 2020. doi: 10.3748/wjg.v26.i32.4763
Immune and microRNA responses to Helicobacter muridarum infection and indole-3-carbinol during colitis
Rasha Raheem Alkarkoushi, Yvonne Hui, Prakash Nagarkatti, Mitzi Nagarkatti, Ioulia Chatzistamou, Marpe Bam, Traci L Testerman, Department of Pathology, Microbiology and Immunology, University of South Carolina School of Medicine, Columbia, SC 29209, United States
Abbas S Tavakoli, College of Nursing, University of South Carolina, University of South Carolina, Columbia, SC 29208, United States
Udai Singh, Department of Medicine, Hematology and Oncology, University of Virginia School of Medicine, Charlottesville, VA 22908, United States
Author contributions: Alkarkoushi RR, Hui Y, Tavakoli AS, Testerman TL and Singh U assisted with conceptualization, performed experiments, analyzed data, and drafted the manuscript; Nagarkatti P and Nagarkatti M assisted with conceptualization and funding acquisition; Chatzistamou I performed histopathological analysis; Bam M analyzed microRNA data; Testerman TL conceptualized assisted with funding acquisition, and wrote and edited the manuscript.
Supported by the National Institutes of Health , No. P20GM103641 .
Institutional review board statement: This study did not involve human subjects.
Institutional animal care and use committee statement: All experimental procedures were conducted in accordance with the guidelines for the use of experimental animals and were approved by the Institutional Review Committee on Animal Care and Use at the University of South Carolina.
Conflict-of-interest statement: The authors have nothing to disclose.
Data sharing statement: Raw data have been provided as supplemental material.
ARRIVE guidelines statement: The authors have read the ARRIVE guidelines, and the manuscript was prepared and revised according to the ARRIVE guidelines.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Corresponding author: Traci L Testerman, PhD, Assistant Professor, Department of Pathology, Microbiology and Immunology, University of South Carolina School of Medicine, 6439 Garners Ferry Road, Columbia, SC 29209, United States. traci.testerman@uscmed.sc.edu
Received: March 19, 2020
Peer-review started: March 20, 2020
First decision: April 8, 2020
Revised: July 16, 2020
Accepted: August 12, 2020
Article in press: August 12, 2020
Published online: August 28, 2020
Processing time: 162 Days and 1 Hours
Peer-review started: March 20, 2020
First decision: April 8, 2020
Revised: July 16, 2020
Accepted: August 12, 2020
Article in press: August 12, 2020
Published online: August 28, 2020
Processing time: 162 Days and 1 Hours
Core Tip
Core tip: The immune response to Helicobacter muridarum (H. muridarum), an enterohepatic Helicobacter species, mimics responses seen during chemically induced colitis and human inflammatory bowel disease (IBD) in terms of local and systemic cytokine responses and microRNA changes. Most microRNAs that are altered in IBD are also altered by H. muridarum infection with or without dextran sodium sulfate treatment. Furthermore, H. muridarum does not alter activity of an aryl hydrocarbon receptor agonist, indole-3-carbinol, a natural compound being explored as a treatment for IBD. Therefore, H. muridarum infection provides a viable model for predicting the effects of enterohepatic Helicobacter species on IBD.